KBC Group NV - CORCEPT THERAPEUTICS INC ownership

CORCEPT THERAPEUTICS INC's ticker is CORT and the CUSIP is 218352102. A total of 231 filers reported holding CORCEPT THERAPEUTICS INC in Q2 2020. The put-call ratio across all filers is 0.94 and the average weighting 0.1%.

Quarter-by-quarter ownership
KBC Group NV ownership history of CORCEPT THERAPEUTICS INC
ValueSharesWeighting
Q3 2023$1580.0%7,1070.0%0.00%0.0%
Q2 2023$158
-6.0%
7,107
-8.5%
0.00%0.0%
Q1 2023$168
-22.6%
7,765
-8.4%
0.00%0.0%
Q4 2022$217
-99.9%
8,4800.0%0.00%0.0%
Q3 2022$217,000
+7.4%
8,4800.0%0.00%0.0%
Q2 2022$202,000
-9.0%
8,480
-14.2%
0.00%0.0%
Q1 2022$222,000
+13.3%
9,8800.0%0.00%0.0%
Q4 2021$196,000
-27.4%
9,880
-28.0%
0.00%0.0%
Q3 2021$270,000
-55.3%
13,718
-50.0%
0.00%0.0%
Q2 2021$604,000
-7.4%
27,4360.0%0.00%0.0%
Q1 2021$652,000
-83.5%
27,4360.0%0.00%
-50.0%
Q4 2020$3,948,000
+561.3%
27,436
-20.0%
0.00%0.0%
Q3 2020$597,000
+3.6%
34,2920.0%0.00%0.0%
Q2 2020$576,000
+182.4%
34,292
+100.0%
0.00%0.0%
Q1 2020$204,000
-65.2%
17,146
-64.6%
0.00%
-50.0%
Q4 2019$587,000
-14.3%
48,4920.0%0.00%
-20.0%
Q3 2019$685,000
+26.6%
48,4920.0%0.01%
+25.0%
Q2 2019$541,000
-4.9%
48,4920.0%0.00%
-20.0%
Q1 2019$569,000
-86.8%
48,492
-84.3%
0.01%
-84.8%
Q3 2018$4,325,000
-25.5%
308,474
-16.4%
0.03%
-34.0%
Q2 2018$5,803,000
+27533.3%
369,140
+5531.4%
0.05%
Q4 2013$21,000
+110.0%
6,5550.0%0.00%
Q3 2013$10,000
-9.1%
6,5550.0%0.00%
Q2 2013$11,0006,5550.00%
Other shareholders
CORCEPT THERAPEUTICS INC shareholders Q2 2020
NameSharesValueWeighting ↓
INGALLS & SNYDER LLC 8,003,723$95,164,0006.41%
TANAKA CAPITAL MANAGEMENT INC 65,609$780,0003.41%
S&T BANK/PA 588,620$6,999,0001.93%
Parallel Advisors, LLC 1,405,895$16,716,0001.35%
Matarin Capital Management, LLC 623,915$7,418,0001.15%
AJ WEALTH STRATEGIES, LLC 668,020$7,943,0001.08%
Capital Impact Advisors, LLC 177,300$2,108,0000.88%
Alambic Investment Management, L.P. 29,547$351,0000.85%
OXFORD FINANCIAL GROUP, LTD. LLC 332,436$3,953,0000.79%
Spark Investment Management LLC 116,400$1,383,0000.74%
View complete list of CORCEPT THERAPEUTICS INC shareholders